4 April 2013
EMA/212211/2013
Human Medicines Development and Evaluation

Public statement on Possia

Withdrawal of the marketing authorisation in the European Union

On 3 December 2010, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Possia, (ticagrelor), which had been approved for the prevention of atherothrombotic events.

The marketing authorisation holder (MAH) responsible for Possia was AstraZeneca AB.

On 27 March 2013, the European Commission issued a decision to withdraw the marketing authorisation for Possia, following its receipt of a letter dated 20 December 2012 notifying the Commission of the MAH's decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons.

Possia was not marketed in any European country.

Pursuant to this decision, the European public assessment report for Possia will be updated to reflect that the marketing authorisation is no longer valid.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8613
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union